Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD3/CD38 bispecific monoclonal antibody IGM-2644

An engineered bispecific, pentameric immunoglobulin M (IgM) monoclonal antibody directed against CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. IGM-2644 consists of ten CD38 binding sites and an anti-CD3epsilon single chain variable fragment (scFv) domain fused to a joining chain. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody IGM-2644 targets and binds to both CD3 on T cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger T-cell dependent cellular cytotoxicity (TDCC) and complement-dependent cytotoxicity (CDC) against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD3/anti-CD38 monoclonal antibody IGM-2644
anti-CD3/CD38 monoclonal antibody IGM-2644
CD38xCD3 bispecific T cell engager IGM-2644
CD38xCD3 bispecific T cell engager IGM-2644
TCE IGM-2644
Code name:IGM 2644
IGM-2644
IGM2644
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search